Please provide your email address to receive an email when new articles are posted on . The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The ...
- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU) - RINVOQ is approved ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...
No new safety risks were identified in the studies. Positive topline results were announced from the phase 3 SELECT-AXIS 2 study evaluating upadacitinib in adults with active ankylosing spondylitis ...
Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA))), Drug Class ...
The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results